Pharmacokinetics and toxicity of idarubicin in the rat

被引:0
作者
Kuhlmann, O
Hofmann, S
Weiss, M [1 ]
机构
[1] Univ Halle Wittenberg, Dept Pharmacol, Sect Pharmacokinet, D-06097 Halle Saale, Germany
[2] Univ Halle Wittenberg, Dept Cardiothorac Surg, D-06097 Halle Saale, Germany
关键词
idarubicin; idarubicinol; rat; lung; pharmacokinetics;
D O I
10.1007/BF03226374
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study was designed to examine the pharmacokinetics and toxicity of idarubicin (IDA) in rats. In two groups of rats IDA was infused either into the V. iugularis interna or into the A. carotis communis, respectively. The venous plasma concentration of IDA and its primary metabolite idarubicinol (IDOL) were measured up to 48 hours by high - performance liquid chromatography (HPLC) with fluorescence detection. The weights of the rats and the levels of haemoglobin, leukocytes, and thrombocytes were recorded. The plasma concentration - time data were analysed, assuming a biexponential disposition curve, both by the traditional (two - stage) method and by population pharmacokinetic modelling. The basic pharmacokinetic parameters clearance (CL = 27.0 ml min(-1)), mean disposition residence time (MDRT = 519.2 min), and volume of distribution at steady state (V-ss = 12.51) were estimated for IDA. The mean residence time (MRT) of the generated IDOL was 2982.5 min. No significant differences between pre- and postpulmonal injection were found in the pharmacokinetics and pharmacodynamics of IDA. The mean survival time of 13.3 days is attributed to a severe myelosuppression.
引用
收藏
页码:215 / 219
页数:5
相关论文
共 50 条
  • [21] Influence of sex on the pharmacokinetics of tolmetin in the rat
    Jiménez, M
    Pérez-Urizar, J
    Flores-Murrieta, FJ
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 1999, 42 (02) : 103 - 105
  • [22] No effect of chloroquine on theophylline pharmacokinetics in the rat
    Motti, BA
    Ashton, M
    BIOPHARMACEUTICS & DRUG DISPOSITION, 1998, 19 (02) : 97 - 100
  • [23] Pharmacokinetics of centhaquin citrate in a rat model
    O'Donnell, J. Nicholas
    Gulati, Anil
    Lavhale, Manish S.
    Sharma, Shyam S.
    Patel, Arjun J.
    Rhodes, Nathaniel J.
    Scheetz, Marc H.
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2016, 68 (01) : 56 - 62
  • [24] β-Escin: An Updated Review of Its Analysis, Pharmacology, Pharmacokinetics, and Toxicity
    Wang, Yunyu
    Han, Xiuwei
    Wan, Xinhuan
    Niu, Fengjv
    Zhou, Changzheng
    AMERICAN JOURNAL OF CHINESE MEDICINE, 2023, 51 (08): : 2095 - 2120
  • [25] DAUNORUBICIN AND DAUNORUBICINOL PHARMACOKINETICS IN PLASMA AND TISSUES IN THE RAT
    CUSACK, BJ
    YOUNG, SP
    OLSON, RD
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 35 (03) : 213 - 218
  • [26] Comparative pharmacokinetics of perfluorononanoic acid in rat and mouse
    Tatum-Gibbs, Katoria
    Wambaugh, John F.
    Das, Kaberi P.
    Zehr, Robert D.
    Strynar, Mark J.
    Lindstrom, Andrew B.
    Delinsky, Amy
    Lau, Christopher
    TOXICOLOGY, 2011, 281 (1-3) : 48 - 55
  • [27] EFFECT OF ISOFLURANE ANESTHESIA ON ANTIPYRINE PHARMACOKINETICS IN THE RAT
    TSE, FLS
    NICKERSON, DF
    AUN, R
    PHARMACEUTICAL RESEARCH, 1992, 9 (11) : 1515 - 1517
  • [28] PLASMA PHARMACOKINETICS OF IDARUBICIN AND ITS 13-HYDROXYMETABOLITE AFTER INTRAVENOUS AND ORAL-ADMINISTRATION UNDER FASTING AND NONFASTING CONDITIONS
    EKSBORG, S
    SODERBERG, M
    NILSSON, B
    ANTILA, K
    ACTA ONCOLOGICA, 1990, 29 (07) : 921 - 925
  • [29] Idarubicin-loaded drug-eluting microspheres transarterial chemoembolization for intermediate stage hepatocellular carcinoma: safety, efficacy, and pharmacokinetics
    Korsic, Spela
    Osredkar, Josko
    Smid, Alojz
    Steblovnik, Klemen
    Popovic, Mark
    Locatelli, Igor
    Trontelj, Jurij
    Popovic, Peter
    RADIOLOGY AND ONCOLOGY, 2024, 58 (04) : 517 - 526
  • [30] PHARMACOKINETICS OF INTRANASALLY-ADMINISTERED DIHYDROERGOTAMINE IN THE RAT
    LAU, DTW
    YU, ZL
    AUN, RL
    HASSELL, AE
    TSE, FLS
    PHARMACEUTICAL RESEARCH, 1994, 11 (11) : 1530 - 1534